πŸ‡ΊπŸ‡Έ FDA
Patent

US 10377817

Human antibodies to GREM1

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10377817 (Human antibodies to GREM1) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K38/179, A61K39/3955